Ientification of Shared Neoantigens in Prostate Cancer

Time: 1:30 pm
day: Pre-Conference Focus Day


  • Data to show critical understanding of the tumor microenvironment to determine response to immune checkpoint therapy in combination with cancer vaccines
  • Identification of VISTA as a potent inhibitory checkpoint that is predominantly expressed on CD68+ macrophages on PDACs, suggesting that VISTA may be a relevant immunotherapy target for effective treatment of patients with pancreatic cancer